Greenland Mines (NASDAQ: GRML) Secures Australian Patent for Klotho Gene Therapy Platform

announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.

To view the full press release, visit: https://nnw.fm/PVbbH

Questions around this news

What is KLTO-202 being developed to treat?
The release identifies amyotrophic lateral sclerosis, or ALS, as KLTO-202’s primary indication and says the program is also intended to target other neuromuscular disorders. It describes KLTO-202 as part of the company’s Klotho-based therapeutic platform, which uses gene therapy technology to support expression of the human Klotho protein.
How does gene therapy work?
Gene therapy aims to treat or prevent disease by changing how genetic information functions in the body. Depending on the approach, it may add genetic instructions, modify existing material, or alter gene activity. Delivery systems help carry the relevant genetic material into target cells, where it may produce a desired biological effect.
What is amyotrophic lateral sclerosis?
Amyotrophic lateral sclerosis (ALS) is a progressive disease that damages motor neurons, the nerve cells that control voluntary muscle movement. As these cells stop working, people can develop muscle weakness and difficulty with movement, speech, swallowing, or breathing. The disease affects people differently, and its progression and care needs vary.

About Greenland Mines

Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

At a glance

Company: Greenland Mines Ltd
Ticker: NASDAQ: GRML
Announcement: Regulatory
Location: Australia

Key figures

Australian patent number: 2023252508

Products and programs

Klotho-based therapeutic platform
KLTO-202

SEC filings

Earlier from Greenland Mines

Back to News Center